Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
复制标题
DOI：
10.1161/circgenetics.111.961144
复制
发表时间：
2012-04-01
影响因子：
--
通讯作者：
Ridker, Paul M.
中科院分区：
文献类型：
--
作者：
Chasman, Daniel I.;Giulianini, Franco;Ridker, Paul M.
背景-在他汀类药物试验中，胆固醇每降低20 mg/dL，血管事件的年发病率就降低10-15%。然而，个体间的变化，低密度脂蛋白胆固醇（LDL-C）对他汀类药物的反应是广泛的，并可能部分地确定在遗传basis.Methods和Results-A全基因组的关联研究LDL-C的反应，共6989名男性和女性的欧洲血统谁被随机分配到瑞舒伐他汀20毫克每天或安慰剂。单核苷酸多态性（SNP）与全基因组关联（P
Background-In statin trials, each 20 mg/dL reduction in cholesterol results in a 10-15% reduction of annual incidence rates for vascular events. However, interindividual variation in low-density lipoprotein cholesterol (LDL-C) response to statins is wide and may partially be determined on a genetic basis.Methods and Results-A genome-wide association study of LDL-C response was performed among a total of 6989 men and women of European ancestry who were randomly allocated to either rosuvastatin 20 mg daily or placebo. Single nucleotide polymorphisms (SNPs) for genome-wide association (P